Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human alpha-lactalbumin is a naturally occurring milk protein that exhibits potent anti-tumor activity when complexed with oleic acid, a form known as HAMLET (Human alpha-lactalbumin made lethal to tumor cells). A synthetic drug candidate, Alpha1H (Alpha1-oleate), which consists of the N-terminal 39 amino acids of the protein complexed with oleic acid, is currently under clinical development. The drug selectively targets malignant cells, inducing apoptosis and inhibiting the expression of cancer-related genes while maintaining a high safety profile for healthy tissues. It has received FDA Fast Track designation for the treatment of non-muscle invasive bladder cancer and has demonstrated significant tumor reduction in Phase II clinical trials. Beyond its therapeutic potential in oncology, human alpha-lactalbumin is also utilized in infant nutrition and functional foods.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human alpha-lactalbumin.